News | October 01, 2009

Positive Outcomes Reported With Supralimus Sirolimus-Eluting Stent With Biodegradable Polymer

Supralimus Sirolimus-Eluting Stent

October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting Stent with a bioabsorbable polymer was highlighted by the company at TCT 2009. The results were released at EuroPCR 2009 earlier this year and demonstrated excellent results in high risk patients with complex coronary lesions, including high procedural success rate (greater than 97 percent), and sustained safety.

Dr. Ricardo A. Costa, of the Cardiovascular Research Center, Brazil, offered preliminary clinical results at six months from the Multicenter E-Series Registry. He said the stent demonstrated clinical effectiveness of Supralimus in preventing revascularization, with only 2 percent target vessel revascularization (TVR) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patient’s in-hospital. The stent thrombosis rate (definite/probable, ARC) up to six months was less than 1 percent.

Out-of Hospital adverse events (N=718) included 2 percent cardiac death, 0.5 percent myocardial infarction (MI) and 4.5 percent of major adverse cardiac event (MACE). Thus the preliminary data with the Supralimus Sirolimus-Eluting Stent has shown promising results, Dr. Costa said.

The study was conducted by Dr. Alexandre Abizaid, Dr. Costa and others from Jan 2007, which involved 1,181 patients with 1,260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years and risk factors included 79 percent hypertension, 38 percent diabetes, 31 percent smoker, 23 percent with previous MI, 64 percent with dyslipidemia, 34 percent with previous PCI and 46 percent with family history of CAD.

For more information: www.smtpl.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init